Ones To Watch News
Refine Search
Biotechnology
San Diego-based iBio, an AI-driven innovator of precision antibody therapies, has announced a licensing agreement with privately-held US biotech AstralBio. 22 April 2025
Biotechnology
US clinical-stage biotech Halda Therapeutics today announced that Dr Eyal Attar has joined the company as chief medical officer (CMO). Dr Attar brings to Halda over 25 years of biotechnology R&D and clinical trial experience in the advancement of novel therapeutics. 22 April 2025
Biotechnology
Japan’s Ono Pharmaceutical and privately-held US firm Jorna Therapeutics are ready to go in a research collaboration agreement that they signed in December of last year. 22 April 2025
Biotechnology
South Korea-based biotech firms 1ST Biotherapeutics and LigaChem Biosciences have entered a strategic partnership to co-develop next-generation antibody-drug conjugates and small molecule immuno-oncology therapies. 22 April 2025
Biotechnology
The US subsidiary of Chinese biotech VelaVigo Cayman Limited has announced its second out-licensing agreement of a first-in-class (FIC) asset, this time to US biotech start-up Ollin Biosciences, granting the latter an exclusive license to develop, manufacture and commercialize VBS-102, a first-in-class bispecific antibody, globally (excluding Greater China). 21 April 2025
Biotechnology
Australian clinical-stage biotech Neurizon Therapeutics, which is advancing innovative treatments for neurodegenerative diseases, has significantly strengthened its executive management team with three key appointments. 18 April 2025
Biotechnology
BigHat Biosciences, a Californian biotech with a machine learning (ML)-guided antibody discovery and development platform, has announced a strategic collaboration with US pharma major Eli Lilly. 17 April 2025
Biotechnology
US cancer drug developer Werewolf Therapeutics today announced the appointment of Steven Bloom as chief business officer (CBOP. 17 April 2025
Pharmaceutical
Florida biopharma Ligand Pharmaceuticals subsidiary Pelthos Therapeutics is to merge with Channel Therapeutics, a developer of non-opioid pain treatments. 17 April 2025
Pharmaceutical
Switzerland-based Addex Therapeutics, a biopharma developing a portfolio of novel small molecule allosteric modulators for neurological disorders, has announced an update on its Phase II asset, ADX71149. 17 April 2025
Biotechnology
US gene therapy company bluebird bio announced that after three weeks of engagement, including a timeline extension, Ayrmid Pharma has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. 17 April 2025
Pharmaceutical
US biotech Wayfinder Biosciences has entered a research collaboration with Japanese drugmaker Daiichi Sankyo to develop small molecule therapies targeting RNA in neurodegenerative diseases. 16 April 2025
Biotechnology
US biotech Myeloid Therapeutics has restructured its operations to concentrate on two cancer programs already in the clinic, a move that has resulted in staff reductions and an uncertain future for its early-stage research work. 16 April 2025
Biotechnology
Californian biotech Glycomine has raised $115 million in a Series C financing to advance its lead candidate, GLM101, into a Phase IIb trial. 16 April 2025
Biotechnology
US biotech Mural Oncology has halted all development of its lead candidate, nemvaleukin alfa, after the engineered cytokine failed to meet the primary endpoint in a Phase II melanoma trial — just weeks after a similar failure in ovarian cancer. The company now plans to explore strategic alternatives, including a potential sale. 16 April 2025
Pharmaceutical
German biotech HepaRegeniX has raised 21.5 million euros ($23 million) in new funding to support the clinical development of its lead candidate, HRX-215, a first-in-class treatment aimed at enhancing liver regeneration. 15 April 2025
Pharmaceutical
Cambridge, USA-based biotech Oak Hill Bio, which is focused on acquiring and developing life-changing rare disease therapeutics, has entered into an exclusive license agreement with Roche to obtain global rights for rugonersen (RO7248824). 15 April 2025
Biotechnology
Privately-held US biotech Attovia Therapeutics, which is developing treatments for immune-mediated diseases with high unmet patient need, today announced the close of a $90 million Series C financing. 15 April 2025
Biotechnology
San Francisco, USA-based inflammatory disease biotech Third Harmonic Bio saw its shares rocket almost 40% to $5.09 as the company revealed an orderly exit plan. 15 April 2025
Biotechnology
German family-owned drug major Boehringer Ingelheim and Cue Biopharma have announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. 15 April 2025
Biotechnology
Capsida Biotherapeutics yesterday revealed US pharma major AbbVie has exercised an option for the first neurodegenerative disease program under their ongoing collaboration. 8 January 2025
Pharmaceutical
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA). 7 January 2025
Pharmaceutical
Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and license agreement for the development and commercialization of Dimerix’ Phase III drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 7 January 2025
Biotechnology
City Therapeutics, a biopharma firm advancing RNA medicines, has named Andrew Orth as its new chief executive officer and director. 7 January 2025
Biotechnology
I-Mab has announced a strategic pivot to prioritize the development of givastomig, a bispecific antibody targeting CLDN18.2 and 4-1BB. 7 January 2025
Biotechnology
Denmark-based macrocycle-drug developer Orbis Medicines today announces the close of a 90 million euros ($94 million) Series A funding round, bringing the total amount raised by the company to 116 million euros. 6 January 2025
Biotechnology
Californian biotech General Proximity announced its emergence from stealth on Friday, unveiling its proprietary OmniTAC platform designed to pioneer the next generation of induced proximity medicines. 6 January 2025
Biotechnology
Austrian arenaviral technology firm HOOKIPA Pharma and Poolbeg Pharma have entered into non-binding discussions for an all-share acquisition by HOOKIPA of London-listed Poolbeg to create a strong clinical-stage biopharmaceutical company. 2 January 2025
Biotechnology
China-based biotech Duality Biologics (DualityBio) yesterday revealed that Sino-American BeiGene has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074. 31 December 2024
Biotechnology
Privately-held immunotherapy company Inmagene Biopharmaceuticals is taking over Ikena Oncology in a reverse merger deal, forming a new company, InmageneBio. 27 December 2024
Biotechnology
California’s AusperBio Therapeutics has secured $73 million in series B financing to propel its lead candidate, AHB-137, an antisense oligonucleotide therapy. 27 December 2024
Pharmaceutical
USA-based clinical-stage biopharma Traws Pharma saw its shares leap more than 150% to $12.57 as it announced progress in the development of its investigational one-dose influenza (flu) investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu. 24 December 2024
Biotechnology
Texan biopharma firm XBiotech has announced a suspension of its clinical program in rheumatology, after its Phase II trial for rheumatoid arthritis failed to meet the primary endpoint. 23 December 2024
Pharmaceutical
New York-based Nuvation Bio today announced that the FDA has accepted the company’s new drug application (NDA) for taletrectinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) for the treatment of advanced ROS1+ NSCLC (line agnostic), for priority review. 23 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 23 December 2024
Pharmaceutical
French pharma major Sanofi says it has entered into a new chapter of the collaboration with South Korean firm SK bioscience in pneumococcal vaccines, with an expanded agreement to develop, license and commercialize next-generation PCVs for both pediatric and adult populations. 23 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 20 December 2024
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze